HPV DNA Test at Chughtai Lab

Understanding the HPV DNA Test at Chughtai Lab

The Human Papillomavirus (HPV) DNA Test is a highly sophisticated molecular diagnostic investigation designed to detect the presence of high-risk strains of the Human Papillomavirus in cervical cells. Human Papillomavirus is one of the most common sexually transmitted infections globally, and persistent infection with high-risk oncogenic genotypes is the primary causative factor in virtually all cases of cervical cancer. At Chughtai Lab, Pakistan’s premier diagnostic network, this test is performed using state-of-the-art Polymerase Chain Reaction (PCR) technology. This advanced molecular method allows for the direct identification of viral genetic material, offering a level of sensitivity and early detection that traditional cytology-based screening methods, such as the conventional Pap smear, cannot achieve on their own.

The primary clinical value of the HPV DNA test lies in its ability to identify women who are at an elevated risk of developing cervical intraepithelial neoplasia (CIN) and subsequent invasive cervical malignancy. By detecting the virus at the molecular level before any visible cellular changes occur under microscopic examination, the test empowers healthcare providers to implement timely monitoring, triage, and therapeutic interventions. This proactive diagnostic approach is a cornerstone of modern preventive gynecology and oncology, significantly reducing the morbidity and mortality associated with cervical cancer. The test evaluates cells collected from the transformation zone of the cervix—the specific anatomical region where the squamocolumnar junction resides and where pre-cancerous lesions are most likely to develop. Through precise genotyping, Chughtai Lab can identify specific high-risk strains, most notably HPV 16 and HPV 18, which are responsible for approximately 70% of all cervical cancer cases globally, alongside other clinically significant high-risk genotypes such as 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the utmost accuracy of the molecular analysis and prevent potential interference with the PCR amplification process, patients must strictly adhere to specific preparation guidelines prior to undergoing the HPV DNA test. Proper preparation minimizes the risk of false-negative results and ensures that the collected cellular sample is adequate for diagnostic evaluation. Patients should observe the following instructions:

• Avoid Menstruation: Schedule the test at least 5 days after your menstrual period has completely ended. The presence of excess blood can obscure cervical cells and interfere with the molecular assay’s chemical reactions.
• Refrain from Sexual Intercourse: Avoid vaginal intercourse for at least 48 hours prior to the procedure, as semen and friction can alter the cervical microenvironment and affect sample quality.
• Avoid Vaginal Products: Do not use tampons, vaginal douching, contraceptive foams, jellies, creams, or any vaginal medications for 48 hours before the test, as these substances can introduce chemical contaminants that inhibit PCR enzymes.
• Hygiene: Cleanse the external perineal area with mild soap and water only; avoid using scented washes or feminine hygiene sprays on the day of the test.
• Communication: Inform your healthcare provider if you are pregnant, have a history of cervical surgeries (such as LEEP or cone biopsy), or are currently treating a vaginal infection.

During the Procedure

The HPV DNA test specimen collection is a straightforward, minimally invasive outpatient procedure that is conducted with the highest standards of clinical hygiene and patient comfort at Chughtai Lab. The entire process typically takes less than five to ten minutes and is performed by experienced female medical staff or gynecologists. The patient is asked to lie on an examination table in the lithotomy position, with feet placed in stirrups. A sterile, lubricated (water-soluble, non-interfering) speculum is gently inserted into the vagina to visualize the cervix clearly. Using a specialized, sterile cervical brush or broom-like collection device, the clinician gently rotates the instrument against the transformation zone of the cervix. This action collects exfoliated epithelial cells from both the ectocervix and the endocervical canal. The collection brush is then immediately immersed and rinsed in a vial containing a liquid transport medium (liquid-based cytology vial) to preserve the cellular and viral DNA. The speculum is then carefully removed, and the procedure is complete. Patients may experience a mild sensation of pressure or brief cramping during the cell collection, and minor spotting may occur immediately afterward, which is entirely normal and self-limiting.

When is an HPV DNA Test Performed?

Routine Cervical Cancer Screening

The primary clinical indication for an HPV DNA test is routine cervical cancer screening in adult women. Leading international medical bodies, including the American College of Obstetricians and Gynecologists (ACOG) and the World Health Organization (WHO), recommend primary HPV screening or co-testing (combining the HPV DNA test with a Pap smear) for women aged 30 to 65 years. Because cervical cancer develops slowly over several years, identifying high-risk HPV strains early allows clinicians to monitor patients closely and intervene long before invasive cancer develops, making this test a vital preventive tool.

Triage of Abnormal Pap Smear Results

When a routine Pap smear yields borderline or ambiguous results, such as Atypical Squamous Cells of Undetermined Significance (ASC-US), the HPV DNA test is performed as a reflex triage investigation. If the HPV DNA test is negative for high-risk strains, the likelihood of an underlying high-grade lesion is extremely low, allowing the patient to return to routine screening. Conversely, a positive high-risk HPV result indicates the need for further diagnostic evaluation, such as a colposcopy and directed biopsy, to check for cervical dysplasia.

Surveillance After Treatment for Cervical Dysplasia

Patients who have undergone therapeutic interventions for high-grade cervical intraepithelial neoplasia (CIN 2 or CIN 3), such as a Loop Electrosurgical Excision Procedure (LEEP) or cold knife conization, require rigorous follow-up monitoring. The HPV DNA test is highly sensitive in detecting residual or recurrent disease. A negative HPV DNA test during post-treatment surveillance provides strong reassurance of successful eradication, while a persistent positive result alerts the oncologist to the potential recurrence of dysplastic lesions.

Evaluation of Persistent High-Risk Symptoms

Physicians frequently request an HPV DNA test for patients presenting with clinical symptoms suggestive of cervical pathology. These symptoms include unexplained post-coital bleeding, intermenstrual bleeding, persistent abnormal vaginal discharge, or chronic pelvic pain. While these symptoms can stem from various benign gynecological conditions, ruling out high-risk HPV infection and associated cervical lesions is a critical diagnostic step in ensuring comprehensive patient care and ruling out early-stage malignancies.

Co-Testing in Women Aged 30 and Older

In women aged 30 and older, the combination of a Pap smear and an HPV DNA test—known as co-testing—is highly utilized. As women age, the likelihood of a transient HPV infection clearing on its own decreases, and the risk of a persistent, oncogenic infection increases. Co-testing provides a dual layer of diagnostic security: the Pap smear evaluates current cellular morphology, while the HPV DNA test identifies the molecular presence of the virus, yielding a near-perfect negative predictive value for cervical cancer over the subsequent five years.

What Does an HPV DNA Test Detect?

The HPV DNA test at Chughtai Lab utilizes advanced molecular assays to detect and differentiate a wide spectrum of Human Papillomavirus genotypes. The test specifically identifies the following clinical parameters and viral markers:

• HPV Genotype 16: The most oncogenic high-risk strain, responsible for the majority of cervical squamous cell carcinomas and adenocarcinomas.
• HPV Genotype 18: A highly aggressive high-risk strain strongly associated with cervical adenocarcinoma and rapid disease progression.
• Other High-Risk Genotypes: Detection of DNA from 12 other high-risk oncogenic strains, including HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.
• Low-Risk Genotypes: Identification of non-oncogenic strains such as HPV 6 and HPV 11, which are primarily responsible for benign laryngeal papillomas and genital warts (condyloma acuminata).
• Viral DNA Integration: Detection of viral genomic sequences integrated into the host cell genome, indicating a persistent and active infection.
• Oncogenic E6 and E7 Gene Activity: Molecular markers associated with the expression of E6 and E7 viral oncoproteins, which degrade host tumor suppressor proteins p53 and Rb.
• Cellular Adequacy: Verification that a sufficient number of human epithelial cells were collected during the sampling process to ensure a reliable molecular reaction.
• Internal Control Amplification: Co-amplification of a human housekeeping gene (such as beta-globin) to confirm the absence of PCR inhibitors in the sample.
• Co-infection Status: Identification of concurrent infections with multiple high-risk HPV genotypes, which may increase the risk of progressive cervical dysplasia.
• Persistent Viral Presence: Comparison with historical test results to confirm whether an infection is transient or has become chronic and persistent.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is widely recognized across Pakistan for its commitment to providing rapid, accurate, and highly accessible diagnostic reporting. Because the HPV DNA test is a specialized molecular assay requiring sophisticated Polymerase Chain Reaction (PCR) amplification and genotyping, the processing time is slightly longer than routine blood tests. Typically, the final verified report is available within 3 to 5 working days from the time of sample collection. Chughtai Lab employs a multi-tiered verification process where molecular biologists and consultant pathologists review every positive result to ensure absolute clinical accuracy.

Patients can access their diagnostic reports seamlessly through Chughtai Lab’s advanced digital healthcare ecosystem. Once the report is finalized and signed off by the consultant pathologist, an automated SMS notification containing a secure link is sent to the patient’s registered mobile number. Reports can be viewed, downloaded, and shared directly via the official Chughtai Lab website or the user-friendly Chughtai Healthcare mobile application. Additionally, Chughtai Lab offers the convenience of receiving reports directly through WhatsApp, eliminating the need for patients to make physical visits to the diagnostic center. For those who prefer physical copies, reports can be collected from any of the numerous Chughtai Lab collection centers located nationwide in major cities including Lahore, Karachi, Islamabad, Rawalpindi, Peshawar, and Multan.

HPV DNA Test Findings Overview

The clinical interpretation of the HPV DNA test is structured to guide subsequent patient management and follow-up protocols. The table below outlines the key parameters evaluated during the molecular analysis, along with their clinical implications:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
HPV Genotype 16 DNA	Not Detected (Negative)	Detected (Positive) – Indicates high risk of cervical intraepithelial neoplasia (CIN); immediate colposcopy is often indicated.
HPV Genotype 18 DNA	Not Detected (Negative)	Detected (Positive) – High association with glandular lesions and adenocarcinoma; requires close clinical evaluation.
Other High-Risk Genotypes (31, 33, 45, 52, 58, etc.)	Not Detected (Negative)	Detected (Positive) – Indicates presence of oncogenic strains; management depends on co-testing cytology and persistence.
Low-Risk Genotypes (6, 11)	Not Detected (Negative)	Detected (Positive) – Associated with benign genital warts; low risk of progression to cervical malignancy.
Internal Control (Beta-globin DNA)	Detected (Positive) – Confirms sample integrity	Not Detected (Negative) – Indicates insufficient sample or presence of PCR inhibitors; repeat collection is required.
Cellular Adequacy	Satisfactory for evaluation	Unsatisfactory for evaluation – Insufficient cervical epithelial cells collected; requires a repeat procedure.
Co-testing Cytology (if performed)	Nil for Intraepithelial Lesion or Malignancy (NILM)	Atypical Squamous Cells (ASC-US/ASC-H), Low-grade (LSIL), or High-grade Squamous Intraepithelial Lesions (HSIL).

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for HPV DNA Test?

When undergoing critical preventive screenings like the HPV DNA test, selecting a highly reliable and accredited diagnostic facility is paramount. Chughtai Lab stands out as Pakistan’s leading healthcare provider due to the following verified features:

• Experienced Healthcare Professionals: Our molecular diagnostics department is staffed by highly trained molecular biologists and led by board-certified consultant pathologists with extensive expertise in virology and oncopathology.
• Patient-Focused Care: We prioritize patient comfort, privacy, and dignity, offering dedicated, private sample collection rooms staffed by professional female clinicians.
• Quality Diagnostic Services: Chughtai Lab adheres to strict international quality standards, participating in rigorous external quality assurance and proficiency testing programs.
• Professional Reporting: Our diagnostic reports are highly detailed, structured, and easy for both patients and referring gynecologists to interpret, facilitating rapid clinical decision-making.
• Modern Diagnostic Approach: We utilize state-of-the-art Real-Time PCR platforms that offer superior analytical sensitivity and specificity for detecting low levels of viral DNA.
• Comfortable Environment: Every Chughtai Lab facility is designed to provide a clean, hygienic, and welcoming environment to minimize patient anxiety.
• Convenient Location: With an extensive network of hundreds of collection centers across Pakistan, finding a Chughtai Lab location near you is simple and convenient.
• Commitment to Accurate Diagnosis: From sample collection and cold-chain transport to molecular amplification and final reporting, we maintain a seamless chain of custody to prevent cross-contamination and ensure absolute accuracy.